Media coverage about Achillion Pharmaceuticals (NASDAQ:ACHN) has trended somewhat positive on Monday, according to Accern Sentiment Analysis. The research firm scores the sentiment of news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Achillion Pharmaceuticals earned a news sentiment score of 0.13 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 47.0117555229655 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the headlines that may have effected Accern’s scoring:
- What the Chart Means for Achillion Pharmaceuticals, Inc. (ACHN) (nismagazine.com)
- Glowing Stock’s Review – Achillion Pharmaceuticals, Inc., (NASDAQ: ACHN) – Stock Watch (stocksnewstimes.com)
- Reviewing the Current Circumstance for Achillion Pharmaceuticals, Inc. (ACHN), Abercrombie & Fitch Co. (ANF) – Market Movers (financialqz.com)
- UPDATE: Achillion Pharma (ACHN) Defended at Leerink – StreetInsider.com (streetinsider.com)
- Glistening Stock’s Review – Achillion Pharmaceuticals, Inc., (NASDAQ: ACHN) – Stock Watch (stocksnewstimes.com)
Achillion Pharmaceuticals (NASDAQ:ACHN) traded down $0.13 during trading hours on Monday, reaching $2.76. 9,775,399 shares of the company were exchanged, compared to its average volume of 1,742,877. Achillion Pharmaceuticals has a 52 week low of $2.69 and a 52 week high of $5.66.
A number of analysts have recently issued reports on ACHN shares. Ladenburg Thalmann Financial Services lowered their target price on shares of Achillion Pharmaceuticals from $9.00 to $6.50 and set a “buy” rating for the company in a research note on Tuesday, September 12th. Zacks Investment Research raised shares of Achillion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.50 target price for the company in a research note on Monday, November 6th. Leerink Swann reissued a “buy” rating and set a $5.00 target price on shares of Achillion Pharmaceuticals in a research note on Monday, December 11th. Chardan Capital reaffirmed a “neutral” rating on shares of Achillion Pharmaceuticals in a research note on Sunday, September 17th. Finally, Robert W. Baird reaffirmed a “neutral” rating and issued a $4.00 price objective (down from $5.00) on shares of Achillion Pharmaceuticals in a research note on Tuesday, September 12th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $5.13.
In other Achillion Pharmaceuticals news, major shareholder & Johnson Johnson sold 18,367,346 shares of the stock in a transaction dated Monday, November 20th. The shares were sold at an average price of $2.75, for a total transaction of $50,510,201.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 7.24% of the stock is owned by corporate insiders.
Achillion Pharmaceuticals Company Profile
Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.
Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.